News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter

Dimethaid Research (DMX.TO) Waives Deadline For Deposit Of Proxies

10/19/2005 5:11:29 PM

TORONTO, Sept. 17 /PRNewswire-FirstCall/ -- To decrease confusion surrounding the solicitation of proxies by a dissident shareholder group, Dimethaid Research Inc. (TSX:DMX) has waived the 9:00 a.m., September 17, 2004 deadline for depositing proxies to be used at the Annual General Meeting. The company has taken this action to make sure all shareholders have an opportunity to exercise their voting rights. Proxies can be submitted any time before 9:00 a.m., EST, September 21, 2004. Shareholders should note that unsubmitted proxies will not count for either side.

Dimethaid urges all shareholders to vote "FOR" management's slate of directors, a recommendation endorsed by Fairvest Corporation, Canada's leading independent proxy advisory firm.

A copy of Dimethaid's management information circular and the accompanying "BLUE" proxy form have been mailed to shareholders and filed with the Canadian securities regulatory authorities at Shareholders who have not received this package should immediately contact Kingsdale Shareholder Services, toll free, at 1-866-749-5464.

Shareholders who have voted for the dissidents can change their vote to support management by contacting Kingsdale.

About Dimethaid

Dimethaid Research Inc. is a publicly traded, Canadian, pharmaceutical company headquartered in Markham, Ontario, with manufacturing facilities in Varennes, Quebec and Wanzleben, Germany. The company develops and commercializes targeted therapeutic drugs designed to produce minimal side effects. Dimethaid's two technology platforms focus on transcellular drug delivery and immune system regulation. Products are aimed at expanding treatment options in rheumatology, dermatology, oncology, immunology, and the therapeutic management of chronic viral infections. For more information, please visit

This release may contain forward-looking statements, subject to risks and uncertainties beyond management's control. Actual results could differ materially from those expressed here. Risk factors are discussed in the Company's annual information form filed with the securities commissions in each of the provinces of Canada. The Company undertakes no obligation to revise forward-looking statements in light of future events.

Dimethaid Research Inc.

CONTACT: Dimethaid Research Inc., Jodi Peake, Manager, IR & CorporateCommunications, Tel: (905) 415-1446 ext. 257; Kingsdale Shareholder Services,Toll-free: 1-866-749-5464, Fax: (416) 867-2271; Renny Ho, Investor RelationsOfficer, Tel: (905) 415-1446 ext. 251, Email:;Archived images on this organization are available through CNW E-Pix at Images are free to members of The Canadian Press;To request a free copy of this organization's annual report, please go to and click on reports@cnw.

Read at

comments powered by Disqus